Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer

CME Activity Information
Release Date:	May 30, 2008
Date Credit Expires:	May 30, 2010
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by May 30, 2010, in order to receive the credit or participation certificate.

1. Assess the strengths and weaknesses of the four main techniques used to measure multiple gene expression using clinical breast cancer specimens.
2. Compare the advantages and disadvantages of the oncotype DX™ and MammaPrint™ multigene assays and compare the TAILORx and MINDACT clinical trials for the prediction of clinical outcome in breast cancer.
3. Evaluate the costs versus benefits associated with the use of expensive multigene breast cancer predictors in the management of breast cancer.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All activity planners, authors, and reviewers are required to submit conflict of interest forms. These forms accompany the activity through the peer review process. Any reviewers who have a conflict of interest are recused. When a reviewer is recused, other suitable reviewers with no self-reported conflicts of interests are selected to conduct the reviews. Editors’ disclosures are published annually online, whereas reviewers’ disclosures are held in confidence within the Editorial Office. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Professor and Chair, Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA;
Disclosures: The author has indicated no relevant commercial relationships.

Christos Hatzis, M.D.

Credentials: Chief Scientific Officer, Nuvera Biosciences, Woburn, Massachusetts, USA.
Disclosures: The author is employed by and owns stock in Nuvera Biosciences (Nuvoselect).

W. Fraser Symmans, M.D.

Credentials: Professor, Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author has ownership and intellectual property in Nuvera BioSciences (Nuvoselect test) and he discloses that the article discusses prognostic/predictive genomic signatures by Genomic Health, Inc, Agendia, and Nuvera Biosciences for breast cancer diagnostics.

Lajos Pusztai, M.D.

Credentials: Associate Professor, Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author is a founder and stockholder of Nuvera Biosciences (Nuvoselect test) and discloses that the article discusses the Affymetrix U133 GeneChip^® System (Affymetrix Corporation) for potential use as a diagnostic test.

Gabriel N. Hortobágyi, M.D.

Credentials: Professor, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Disclosures: The author has indicated no relevant commercial relationships. The author also discloses that except for oncotype DX™ and MammaPrint^®, all predictors described in the article are investigational and the indications are evolving.

• Take this course